Baseline clinical traits for the total study population. With the 240 individualsBaseline clinical traits for

Baseline clinical traits for the total study population. With the 240 individuals
Baseline clinical traits for the total study population. With the 240 sufferers switched to lurasidone from other antipsychotics, 235 individuals with offered data on the PETiT scale and SF-12 assessment comprised the ITTAwad et al. BMC Psychiatry 2014, 14:53 http:biomedcentral1471-244X14Page four ofTable 1 Patient demographics and baseline clinical characteristicsParameter N Imply age Years, SD Gender Male Female Race Asian Black or African American Native Hawaiian or other Pacific Islander White Other DSM-IV Schizophrenia subtype diagnosis 295.10 Disorganized variety 295.20 Catatonic type 295.30 Paranoid variety 295.60 Residual kind 295.70 Schizoaffective disorder 295.90 Undifferentiated sort Preswitch antipsychotic agent at study start out Quetiapine Risperidone Aripiprazole Ziprasidone Olanzapine Paliperidone Iloperidone Asenapine First-generation antipsychotic Therapy with concomitant lithium, valproate or lamotrigine Therapy with concomitant antidepressant Mean age (SD) at initial onset of schizophrenia or schizoaffective disorder, years Imply optimistic and negative syndrome scale total score (SD) Imply clinical global impression severity score (SD)or as indicated.83 of 235 (35 ) were treated with a preswitch sedating medication (olanzapine or quetiapine).PETiT KDM3 Compound assessmentNo. of subjects ( )43.9 (10.9)156 (65.0 ) 84 (35.0 )1 (0.four ) 151 (62.9 ) 1 (0.four ) 80 (33.3 ) 7 (2.9 )The mean (common deviation [SD]) PETiT total score for all lurasidone individuals enhanced from 35.0 (8.eight) at baseline to 38.five (9.2) at LOCF endpoint, representing a mean improvement of 3.two (eight.five) or 9.1 (p 0.001). Improvements from baseline to LOCF endpoint inside the total score, at the same time as within the domains of adherence-related attitude (0.7 [2.6]) and psychosocial functioning (2.five [6.9]), were statistically considerable (p 0.002) for all individuals who have been switched to lurasidone (Table two). All elements with the psychosocial functioning domain (activity, cognitive, and dysphoria) showed significant improvement (p 0.002) with all the exception of social functioning, where a non-significant improvement was demonstrated.PETiT scores by preswitch antipsychotic medication4 (1.7 ) 0 125 (52.1 ) 2 (0.eight ) 89 (37.1 ) 21 (eight.8 )62 (25.eight ) 51 (21.three ) 44 (18.3 ) 27 (11.3 ) 24 (ten.0 ) 9 (three.eight ) 4 (1.7 ) two (0.8 ) 17 (7.1 ) 34 (16.two ) 104 (43.three ) 25.1 (9.3) 68.9 (13.eight) three.7 (0.five)The differences in patients’ PETiT scores have been also stratified determined by the antipsychotic medication applied prior to switching to lurasidone. To ensure a reasonable sample size for this evaluation, preswitch antipsychotic medicines received by 10 of individuals within the study have been incorporated for stratification. The medicines integrated quetiapine (n = 62), risperidone (n = 51), aripiprazole (n = 44), ziprasidone (n = 27), and olanzapine (n = 24). Individuals on all of those preswitch drugs except olanzapine showed statistically significant improvements in total PETiT scores, as determined by imply alterations from baseline to LOCF ( D): quetiapine 4.two (7.7), p = 0.011; risperidone three.6 (7.9), p = 0.029; aripiprazole three.4 (8.0), p = 0.010; ziprasidone 5.4 (7.9), p = 0.009 (Table three). Sufferers on these 4 agents also showed substantial improvements around the psychosocial functioning element (all p 0.05) (Table 3). For patients switched from olanzapine, a numerical decrease in the total PETiT score and its CDK14 drug components was observed; on the other hand, this distinction was not statistically substantial. Sufferers in the aripiprazole and ziprasidone preswi.